CLAM Chemotherapy With PBSC Support for Relapsed Patients After Allogeneic Stem Cell Transplantation
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
For acute leukemia patients with early relapse after allogeneic stem cell transplantation,
the overall outcome is poor. In this study, we evaluate the treatment outcome and safety of
chemotherapy with Cladribine, cytarabine and mitoxantrone followed by peripheral stem cell
support from the original donor.